Compare FLXS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | VYGR |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 220.3M | 222.4M |
| IPO Year | 1995 | 2015 |
| Metric | FLXS | VYGR |
|---|---|---|
| Price | $55.41 | $3.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 38.0K | ★ 571.1K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ 85.86 | N/A |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $441,073,000.00 | $10,135,000.00 |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | $4.07 | $71.77 |
| P/E Ratio | $21.84 | ★ N/A |
| Revenue Growth | ★ 6.86 | N/A |
| 52 Week Low | $29.38 | $2.65 |
| 52 Week High | $59.95 | $5.55 |
| Indicator | FLXS | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 66.48 | 33.59 |
| Support Level | $53.38 | $3.31 |
| Resistance Level | $58.08 | $3.91 |
| Average True Range (ATR) | 3.37 | 0.22 |
| MACD | 0.97 | -0.04 |
| Stochastic Oscillator | 74.50 | 6.41 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.